TargetBeta
PPARD
peroxisome proliferator activated receptor delta · also NUC1, NUCII, FAAR, NR1C2 · Peroxisome proliferator activated receptors
5 programs in company-led studies act on PPARD, from 5 companies: 5 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| elifibranorrule | Genfit | phase 3 | 245 running | PPARA | ChEMBL |
| seladelparrule | Gilead Sciences | phase 3 | 143 running | PPARA | ChEMBL |
| lanifibranor | Inventiva Pharma | phase 3 | 61 running | PPARA, PPARG | the company's pipeline |
| T3D-959rule | T3D Therapeutics | phase 3 | 31 running | PPARG | ChEMBL |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 90 running | PPARA, PPARG | ChEMBL |
Conditions their studies are in
- Non-alcoholic Fatty Liver Disease, 3 programs
- Cholangitis, Sclerosing, 2 programs
- Diabetes Mellitus, Type 2, 2 programs
- Liver Cirrhosis, Biliary, 2 programs
- Renal Insufficiency, 2 programs
- Alzheimer Disease, 1 program
- Homozygous Familial Hypercholesterolemia, 1 program
- Hyperlipidemias, 1 program
- Scleroderma, Diffuse, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 17, 2026elifibranor · Genfit · phase 3 · NCT06730061
- Nov 2028seladelpar · Gilead Sciences · phase 3 · NCT03301506
- Apr 2031T3D-959 · T3D Therapeutics · phase 3 · NCT06964230
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.